Management of idiopathic, diabetic and miscellaneous gastroparesis with cisapride.
There have been several long term studies (greater than 4 weeks) of cisapride in a variety of gastroparetic conditions. All of these studies have used cisapride 10 mg t.i.d. or q.i.d. Chronic idiopathic dyspepsia Cisapride has been shown to be effective in both improving symptoms and also delayed gastric emptying in a six week study. In another placebo controlled study of two weeks, gastric emptying was improved but symptoms did not improve significantly. Diabetic gastroparesis In a four week study, cisapride has been shown to be effective in improving symptoms and solid phase gastric emptying. A six weeks study demonstrated both improvement of solid and liquid gastric emptying and symptoms. Progressive systemic sclerosis Cisapride was effective in improving symptoms over a four week period. Myotonic dystrophy Cisapride was effective in improving solid phase gastric emptying and symptoms over a four week period. Combined studies In two combined studies, cisapride has been shown to be effective in a variety of gastroparetic conditions. One year studies In three open long term studies, cisapride appears to be the first prokinetic agent to demonstrate long term efficacy for up to one year.
Champion
M C
MC
Ottawa Civic Hospital, University of Ottawa, Ontario, Canada.
D020117:Cisapride; D002986:Clinical Trials as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004294:Domperidone / Q000627:therapeutic use; D005746:Gastric Emptying / Q000187:drug effects*; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D010880:Piperidines; D012702:Serotonin Antagonists; D004294:Domperidone; D008787:Metoclopramide; D020117:Cisapride